This therapy involves the administration of LNP-encapsulated mRNA encoding cas9 protein and gRNA targeting misfolded transthyretin (TTR), a protein predominantly accumulated in the heart and nerves of transthyretin amyloidosis patients. The gene discussed is TTR; the disease is amyloidosis.